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PUK10
GENERIC AZATHIOPRIN FOR KYDNEY TRANSPLANT PATIENTS—
ANALYSIS OF COST SAVINGS
Georgieva SS1, Stoimenova A2, Petrova GI2
1Aleksandrovska Hospital, Soﬁ a, Bulgaria; 2Medical University, Faculty of Pharmacy, Soﬁ a, 
Bulgaria
OBJECTIVES: To analyze the cost savings after an introduction of the generic version 
of azathioprin for patients with transplanted kidney. METHODS: Prospective obser-
vational study of the cost of pharmacotherapy of patients was performed during 
2009–2010. It was collected information for 121 patients previously treated with the 
originator and transferred to the generic medicines. The patient sample was system-
atized according to patient age, gender, additional medicines used for main therapy, 
and monthly cost of pharmacotherapy. RESULTS: The average monthly cost of the 
combined immunosuppressing therapy when the original product was included was 
c320.99 and after the introduction of the generic version it became c311.29. On the 
other hand the monthly cost of the therapy only with azathioprin changed from c6.71 
to c5.78 per patient per month. The patients’ number varies among 121 to 96 during 
different months due to the drop out. After the introduction of the generic version 7 
patients were switched to another immunosuppressive agent, while for the originator 
the corresponding ﬁ gure is 2 patients. For the switched patients the cost of pharma-
cotherapy did not increase. CONCLUSIONS: In spite of the contradictory introduc-
tion of generic versions of immunosuppressors, due to their narrow therapeutic index 
the drop out of the patients is not higher and the savings for the health care system 
are possible.
PUK11
A COST EVALUATION OF PERITONEAL DIALYSIS AND HEMODIALYSIS 
IN THE TREATMENT OF ESRD IN SÃO PAULO, BRAZIL
Ferraz MB1, Mendes de Abreu M2, Walker DR3, de Castro Cintra Sesso R1
1Universidade Federal de São Paulo, Sao Paulo, SP, Brazil; 2Universidade Federal de Sao 
Carlos, Sao Carlos, SP, Brazil; 3Baxter Healthcare Corporation, McGaw Park, IL, USA
OBJECTIVES: ESRD patient survival is similar for hemodialysis (HD) and peritoneal 
dialysis (PD). In Brazil, access to dialysis is universal, although the resources consumed 
and their costs are poorly understood. We compare the resources used for the treat-
ment of patients undergoing HD or PD who are covered by public insurance. 
METHODS: A one-year prospective study comparing resource use and total costs of 
prevalent patients treated with HD (n = 210) and PD (n = 194) was conducted in 5 
dialysis units in Sao Paulo, Brazil. Inclusion criteria: ≥18 years of age and clinically 
stable on chronic dialysis. The study period was April 2007 to February 2009. Data 
were obtained at baseline, 6 and 12 months using surveys and medical records. Cost 
categories included hospitalizations, diagnostic and therapeutic procedures, medica-
tions, professional fees, transportation, and lost productivity (current homemakers 
who stopped working due to dialysis). Government reimbursement rate was used as 
a proxy for the direct costs related to the act of dialysis (maintenance). The study took 
the societal perspective. RESULTS: Approximately 50% of HD and 48% of PD 
patients were female (p = 0.75); 54% and 58% were white (p = 0.48); mean age was 
55.2 and 60.6 (P < 0.001); 62% and 71% had diabetes (p = 0.0528); and 59% and 
55% had coronary heart disease (p = 0.37), respectively for HD and PD. Overall 
average costs per patient-year of follow up was US$23,283 for HD and US$23,285 
for PD patients. The average annual cost per patient-year, per category, for HD and 
PD were respectively, US$11,774 and US$14,058 for maintenance dialysis costs; 
US$9,208 and US$7,559 for medications; US$94 and US$43 for hospitalization, 
US$796 and US$487 for travel costs and $US323 and $264 for current homemakers 
lost income due to dialysis. CONCLUSIONS: Mean annual total cost of PD and HD 
are nearly identical, even though the former were signiﬁ cantly older and more 
diabetic.
PUK12
THE ECONOMIC IMPACT OF RENAL GRAFT FAILURE: A COST 
ANALYSIS IN A UK SETTING
Sun Y1, Cerri K2
1London School of Economics and Political Science, London, UK; 2Bristol-Myers Squibb, 
Braine-l’Alleud, Belgium
OBJECTIVES: Compared to dialysis, kidney transplantation is a highly cost-effective 
choice for most patients with ESRD. Post transplantation, a key objective is to main-
tain a functioning graft. When graft failure occurs, the majority of patients return to 
dialysis. This study is performed to assess the cost of renal graft failure in a UK setting. 
METHODS: A model was built using data from the UK renal registry (2007–2008) 
to estimate the number of graft failures occurring in the ﬁ rst year after transplantation. 
Costs for procurement, transplantation, and for the treatment of graft failure, were 
derived from the result of a systematic review. This study adopted an investment 
perspective—all the medical resource used from organ procurement to the treatment 
of graft failure were taken into consideration. RESULTS: In the UK, the cost of renal 
graft failure was approximately £58,847 when taking account the medical resource 
used from an investment point of view (including transplantation cost, immunosup-
pressive medication cost and resource to treat post transplantation adverse events for 
graft failure patients). The post graft failure cost was £28,179. The most important 
cost contributors are dialysis cost, transplantation cost and post transplantation 
immunosuppressive medication cost. CONCLUSIONS: Estimating the economic 
impact of graft loss should take into account the cost of management of patients post 
graft failure, as well as previous medical investment that is lost with the graft (includ-
ing costs associated with procurement of the organ and transplantation). Improve-
ments in the management of renal transplant patients are needed to reduce the risk 
of graft loss and the economic burden of graft failure to the health care system.
PUK13
INCIDENCE AND COST OF HOSPITALIZATIONS FOR ACUTE URINARY 
RETENTION ATTRIBUTABLE TO BENIGN PROSTATE HYPERPLASIA IN 
FRANCE
Cotté FE1, Torreton E2, Lafuma A3
1GlaxoSmithKline, Marly le Roi, France; 2CEMKA-EVAL, Paris, France; 3CEMKA-EVAL, Bourg 
la Reine, France
OBJECTIVES: Acute urinary retention (AUR) is one of the most signiﬁ cant complica-
tions of long-term benign prostatic hyperplasia (BPH) and often leads to prostate 
surgery. AUR also represents an important and feared event that needs to be quantiﬁ ed 
from an economic perspective as well as from the viewpoint of BPH patients. 
METHODS: French hospital information program (PMSI) databases from 2005 to 
2008 were used to assess the number of hospitalizations for AUR and their manage-
ment among males ≥50 years old presenting with a diagnosis of BPH. Number of 
patients concerned and rates of re-hospitalizations and deaths due to AUR were 
estimated using the linking system of the PMSI. Cost estimation was performed for 
the year 2008 adopting the Sickness Funds perspective. RESULTS: During the 4-year 
period, AUR frequency increased to 38,914 hospitalizations (+20.5%, +8.2%, +1.2% 
compared with 2005, 2006 and 2007, respectively). In 2008, mean length of stay was 
5.5 ± 6.9 days and decreased of 6.6% within the study period. Proportion of stays 
referred by emergency department was 28.8% (14.1%, 20.6%, 25.3% in 2005, 2006 
and 2007, respectively). 26,581 males were concerned by at least one AUR (+15.4%, 
+5.9%, +0.0% compared with 2005, 2006 and 2007, respectively) of whom 32.6% 
were concerned by a recurrence (28.9%, 30.7%, 31.4% in 2005, 2006 and 2007, 
respectively). Mean age was 74.1 years (SD:10.4) (stable over the period) and 232 
patients (0.9%) deceased during their hospitalization in 2008. Mean cost per patient 
in 2008 was c2400 (c2663 vs. c1997 in public and private hospitals, respectively). 
Global cost of hospitalizations for RAU was estimated at c93.4 million (67.2% in 
public hospitals). CONCLUSIONS: AUR attributable to complicated BPH globally 
increased but tend to become stable in 2008. However, proportion of emergency 
utilization and recurrent stays ampliﬁ ed. Despite appropriate available therapies, 
prevention of BPH complications remains suboptimal.
PUK14
HEALTH CARE COST OF RENAL REPLACEMENT THERAPY IN 
HUNGARY
Kalo Z1, Kiss Z2, Gerendy P2, Nagyjanosi L3, Vokó Z1
1Eötvös Loránd University, Budapest, Hungary; 2National Health Insurance Fund 
Administration, Budapest, Hungary; 3Syreon Research Institute, Budapest, Hungary
OBJECTIVES: Annual cost of renal replacement therapy is an important benchmark 
for public reimbursement of all health care services. The last report was presented 
more than 10 years ago in Hungary, so our objective was to calculate the current 
annual cost of waiting listed dialysis and renal transplantation. METHODS: We 
selected all waiting listed or renal transplanted patients between July 2004 and March 
2008. Resource utilization of all health care services with public reimbursement per 
patient in Q1 2008 were aggregated by linking claims records with anonimised patient 
IDs. We calculated health care costs of waiting listed and renal transplanted patients. 
Results were adjusted to gender, age and onset of ESRD by multivariate regression 
analysis. a total of 135 HUF/USD GDP speciﬁ c PPP exchange rate was employed to 
convert results into USD. 2008 cost calculations were compared to results of the 1997 
analysis. RESULTS: A total of 2209 patients were selected to the analysis. 3 year cost 
of waiting listed dialysis and renal transplantation was US$110,742 and US$87,420 
respectively. Renal transplantation is cost-saving within 2 years compared to dialysis. 
CONCLUSIONS: Between 1997 and 2008 the 3-year cost of waiting listed dialysis 
increased by 60.3%, 3-year cost of renal transplantation increased by 96,8% without 
correction for inﬂ ation. In real values the health care costs waiting listed dialysis and 
renal transplantation is reduced by 26.7% and 10,0%. During this period the cost-
containment measures of the National Health Insurance Fund were successful.
PUK15
RESOURCE USE AND COSTS OF PATIENTS UNDERGOING DIALYSIS IN 
BELGIUM
Caekelbergh K1, Lamotte M1, Dratwa M2, Bogaert AM3, Bouman K4, Laplante S5
1IMS Health Consulting, Brussels, Belgium; 2CHU Brugmann, Brussels, Belgium; 3AZ St 
Elisabeth, Zottegem, Belgium; 4ZNA Middelheim, Antwerpen, Belgium; 5Baxter Healthcare 
Corporation, Braine l’Alleud, Belgium
OBJECTIVES: This study was conducted to identify and compare resources and costs 
used by dialysis patients in Belgium. METHODS: The records of 130 patients under-
going dialysis were retrospectively reviewed to identify direct medical and non-medical 
resources used over year 2006. Data collected: baseline medical characteristics, dial-
ysis-related information and resources used (hospitalizations, ambulatory care, medi-
cation, transport). Ofﬁ cial tariffs were used for costing. RESULTS: Patients were 
hospitalized 1.5 ± 1.7 times for 18.1 ± 29.1 days. Laboratory tests were performed 
more frequently in hemodialysis (HD) patients than in peritoneal dialysis (PD) patients 
(295.6 ± 137.7 vs. 120.1 ± 75.5; P < 0.0001). Patients on HD took more medications 
(12.4 ± 3.7 vs. 10.7 ± 4.3; P = 0.0254). 79% of patients received EPO (average dose: 
10,587 ± 14,114 IU). Patients on PD had more ambulatory consultations (9.7 ± 8.8 
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vs. 4.6 ± 8.9; P = 0.0029) and interventions (5.8 ± 11.1 vs. 0.7 ± 1.1; P = 0.0042). 
Only 11.6% of PD patients used an ambulance or transport organized by the dialysis 
center/sickness fund, compared with 67.8% for HD. The estimated annual cost for 
the public payer (PP) was c72,350 per HD and c55,343 per PD patient (i.e., 31% 
more). As in 2006 there were approximately 6400 patients on dialysis (90% on HD, 
10% on PD), the PP total cost is estimated to be around c452 million (2.45% of 2006 
health care budget). The dialysis procedure was the main cost driver (66% of costs) 
being 27% more expensive for HD. Hospital and ambulatory services were respec-
tively 28% and 45% more expensive for HD. CONCLUSIONS: The economic burden 
of dialysis is important in Belgium. Considering that survival of PD patients is at least 
as good as that of HD patients and that home-treatment reduces exposure to hospital 
pathogens, PD represents good value for money and should be considered in more 
patients.
PUK16
COST OF ILLNESS ASSOCIATED WITH RENAL TRANSPLANTATION 
AND DIALYSIS IN END STAGE RENAL DISEASE IN THE UNITED 
STATES
Srivastava K, Sharma S, Ahuja A, Taneja A
Heron Health Private Ltd, Chandigarh, India
OBJECTIVES: A patient suffering from end stage renal disease (ESRD) has two treat-
ment options, lifelong dialysis or renal transplantation. The aim of this review is to 
determine economic cost of illness associated with renal transplantation and dialysis 
in ESRD in the United States (US). METHODS: The information was retrieved from 
databases including Medline, EMBASE, United States Renal Data System (USRDS), 
WHO and relevant grey literature. Studies reporting data for cost associated with 
transplantation and dialysis in ESRD in the US were included. RESULTS: In 2007, 
hemodialysis (HD) was initiated in 99,886 patients, peritoneal dialysis (PD) in 6376 
patients and transplantation in 2500 patients in the US. Total Medicare costs associ-
ated with these were $17.6 billion for HD, $949 million for PD and $1.9 billion for 
transplantation (USRDS 2009). Unadjusted average annual Medicare expenditure 
(2004 US$) for PD and HD as ﬁ rst modalities was $53,277 and $72,189 respectively 
(Shih 2005). Patients with HD were twice as likely to be hospitalised over a 12-month 
period compared to matched PD patients. The median health care costs associated 
with hospitalization were $173,507 for HD patients vs. $129,997 for PD patients 
(Berger 2009). The mean length of stay was signiﬁ cantly less for PD with 6.57 days 
(P < 0.0001) vs. 7.25 days for HD (Walker 2009). The mean cost of treating S. aureus 
bacteraemia in HD patients, including readmissions and outpatient costs, was $24,034 
per episode (Engemann 2005). Over a 25 year time horizon, renal transplantation 
resulted in signiﬁ cant cost savings with a cost of $376,577/patient and life expectancy 
of 7.4 years compared to $568,670/patient and life expectancy of 6.7 years with long 
term dialysis (Quinn 2007). CONCLUSIONS: Renal transplantation results in signiﬁ -
cant cost savings compared to long term dialysis. The total health care costs associated 
with hemodialysis are higher compared to peritoneal dialysis.
PUK17
PATIENT CO-MORBIDITIES AFFECT THE COST OF DIALYSIS PATIENTS 
IN BELGIUM
Laplante S1, Walker DR2, Caekelbergh K3, Lamotte M3, Dratwa M4, Bogaert AM5, 
Bouman K6
1Baxter Healthcare Corporation, Braine l’Alleud, Belgium; 2Baxter Healthcare Corporation, 
McGaw Park, IL, USA; 3IMS Health Consulting, Brussels, Belgium; 4CHU Brugmann, Brussels, 
Belgium; 5AZ St Elisabeth, Zottegem, Belgium; 6ZNA Middelheim, Antwerpen, Belgium
OBJECTIVES: This analysis was done to assess if co-morbidities inﬂ uence the public 
payer (PP) cost of dialysis patients in Belgium. METHODS: The data from a cost 
study (retrospective chart review of 130 Belgian patients undergoing dialysis in 2006) 
was analyzed a posteriori. Baseline medical characteristics were used to compute the 
Charlson co-morbidity score (CCMS). Costs included: dialysis procedure and medical 
management (i.e., hospitalizations, outpatient visits and procedures, laboratory and 
imaging tests, and transport). Multivariate analyses were performed with the logarith-
mic transformation of costs as the dependent variable and CCMS, dialysis modality 
(hemodialysis: HD or peritoneal dialysis: PD) and gender as the independent variables. 
The regression model was weighted by number of patient months in the study. CCMS 
was categorized as low (<4), moderate (4–5), high (6–7) and very high (> = 8). 
RESULTS: All 3 variables had a signiﬁ cant impact on costs. Total costs to the PP were 
16% higher for HD than for PD patients (p = 0.0039) and were 13% higher in women 
than in men (p = 0.0207). The costs in patients with a very high CCMS were 21% 
higher than those with a low or moderate score (p = 0.0072 and p = 0.0094 respec-
tively) and 10.7% higher than those with a high score, but this latter difference did 
not reach statistical signiﬁ cance (p = 0.1160). The differences were larger when exclud-
ing the cost of dialysis procedure and considering medical management only, but only 
reached statistical signiﬁ cance or patients having a very high CCMS score vs. low or 
moderate CCMS (p = 0.0036 and 0.0056 respectively). CONCLUSIONS: This analy-
sis showed that patient co-morbidities have a signiﬁ cant impact on medical manage-
ment and total costs of dialysis patients. It is therefore important to take this into 
consideration when studying the costs of dialysis patients, especially if a total cost 
approach (i.e., procedure plus medical management) is taken.
PUK18
COST-EFFECTIVENESS ANALYSIS OF TIMELY VERSUS LATE DIALYSIS 
REFERRAL AFTER RENAL TRANSPLANT FAILURE IN SPAIN
Villa G1, Fernández-Ortiz L1, Cuervo J1, Rebollo P1, Sánchez-Álvarez E2, Ortega F2
1BAP Health Outcomes Research, Oviedo, Spain; 2Hospital Universitario Central de Asturias, 
Oviedo, Spain
OBJECTIVES: Complications due to late dialysis referral after graft loss involve higher 
medical costs, together with a worsened health status and higher mortality rates. The 
efﬁ ciency of timely (TDR) versus late dialysis referral (LDR) after renal transplant failure 
is evaluated for the Spanish case. METHODS: A Markov model was developed and 6 
health states were deﬁ ned: hemodialysis (HD), peritoneal dialysis (PD), transplant (TX), 
late referral hemodialysis (LRHD), late referral peritoneal dialysis (LRPD) and death 
(D). a hypothetical cohort of patients aged 45 was observed during 40 years, considering 
age-dependent mortality rates. Transition probabilities were estimated using data from 
the Spanish Nephrology Society registry. Costs (in 2009 EUR) were obtained from a 
comprehensive literature review and included both direct (DC) (medical and non-
medical) and indirect costs (IC) (lost labor productivity due to mortality and morbidity). 
Effectiveness was measured in terms of Quality Adjusted Life-years (QALYs). Health 
utilities were estimated from a proprietary database. a discount rate of 3.5% was 
considered for both cost and effectiveness ﬁ gures. All the model parameters were sup-
ported by an expert panel. Incremental Cost-Effectiveness Ratios (ICERs) and Net 
Health Beneﬁ ts (NHBs) were computed. a willingness-to-pay threshold of c35,000/
QALY was taken into account. Both univariate and Monte Carlo multivariate sensitivity 
analyses were performed. RESULTS: The ICER was c27,385/QALY (IC not included) 
and c34,051/QALY [IC included], providing NHBs of (0.08) [0.01]. TDR yielded 0.37 
additional QALY/patient. The multivariate sensitivity analysis showed that TDR was 
efﬁ cient in (54%) [53%] and dominant in (28%) [27%] of the simulations. The prob-
ability of accepting TDR was (55%) [50%]. CONCLUSIONS: TDR is an efﬁ cient 
scenario when compared to LDR, providing a greater number of QALYs with yet an 
affordable increase in costs. Our results, however, raise the debate on the suitability of 
the willingness-to-pay threshold as a rigid decision tool.
PUK19
ECONOMIC EVALUATION OF ALISKIREN IN TYPE 2 DIABETES AND 
HYPERTENSION PATIENTS WITH NEPHROPATHY IN MEXICO
Nevarez A1, García-Contreras F1, Olvera K2
1Mexican Institute of Social Security, Mexico City, D.F., Mexico; 2Novartis, Mexico City, D.F., 
Mexico
OBJECTIVES: To determine the most cost-effective alternative between a) Losartan, 
and b) Losartan + Aliskiren in type 2 diabetes and hypertension patients with micro-
albuminuria in the Mexican Institute of Social Security. METHODS: A complete 
economic evaluation was performed from institutional perspective, using a Markov 
model as analytical tool with semi-annual cycles and follow up until death, with 
transversal analyses at 10, 15 and 20 years. Simulating a cohort with a 53 years old 
patient with type 2 diabetes, hypertension, and microalbuminuria and using a dis-
counting rate of 5% in costs and effectiveness. One assumption is that all patients 
that require dialysis receive it. Proportion of patients who have not received dialysis, 
as well as survival and quality of life were considered as effectiveness end points. 
Transition probabilities were obtained from AVOID study and IMSS information. 
Resource use was obtained from IMSS data and costs are considered in 2009 USD. 
Probabilistic and non-probabilistic sensitivity analysis was performed. RESULTS: 
Keeping a patient in stages prior to dialysis at 20 years of follow-up requires an 
investment of $19,647 with Losartan and $18,774 with Losartan + Aliskiren. After 
14 years of follow up, Aliskiren + Losartan is dominant versus the use of Losartan. 
CONCLUSIONS: Aliskiren + Losartan is a cost-saving alternative if administered for 
prolonged periods, being the most effective regardless the period of monitoring and 
effectiveness measurement used.
PUK20
THE COST-EFFECTIVENESS OF LANTHANUM CARBONATE VS. 
SEVELAMER HYDROCHLORIDE IN PATIENTS WITH END-STAGE RENAL 
DISEASE
Park H1, Rascati KL1, Keith MS2, Hodgkins PS2, Smyth MD3, Goldsmith D4, Akehurst RL5
1The University of Texas at Austin, Austin, TX, USA; 2Shire Pharmaceuticals, Wayne, PA, 
USA; 3Shire Pharmaceuticals, Basingstoke, UK; 4Guy’s Hospital London, London, UK; 5The 
University of Shefﬁ eld, Shefﬁ eld, UK
OBJECTIVES: To assess the cost-effectiveness between two non-calcium binders, 
lanthanum carbonate (LC) and sevelamer hydrochloride (SH), in end-stage renal 
disease (ESRD) patients previously treated with calcium-based binders. METHODS: 
A Markov model was developed to estimate incremental costs for three health out-
comes: 1) quality-adjusted life-years (QALYs), 2) Life-years saved (LYS) and 3) percent 
who successfully met serum phosphorus (SP) level goals (3.5–5.5 mg/dl) between the 
two non-Ca binders. The model incorporated patient-level data from a randomized 
head-to-head crossover study which compared the reduction of SP using ﬁ xed doses 
of LC for 4 weeks. For this analysis the model included patients previously treated 
with calcium-based binders. The ‘intent-to-treat’ (ITT) population and the ‘completer’ 
population were assessed. Baseline risks of cardiovascular disease (CVD), overall 
mortality, and CVD mortality were derived from a large US epidemiological study. 
Utilities, costs and relative risks of CVD were derived from published sources. Patient 
outcomes were modeled for 10 years, and incremental cost-effective ratios (ICERs) 
were calculated for LC relative to SH. Clinical and economic outcomes were dis-
